These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26238439)

  • 1. What to expect from high throughput genomics in metastatic breast cancers?
    Onesti CE; Vicier C; André F
    Breast; 2015 Nov; 24 Suppl 2():S19-22. PubMed ID: 26238439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision medicine for metastatic breast cancer.
    Deluche E; Onesti E; Andre F
    Am Soc Clin Oncol Educ Book; 2015; ():e2-7. PubMed ID: 25993174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative genomic analysis of primary tumors and metastases in breast cancer.
    Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
    Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
    Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
    Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision medicine for metastatic breast cancer--limitations and solutions.
    Arnedos M; Vicier C; Loi S; Lefebvre C; Michiels S; Bonnefoi H; Andre F
    Nat Rev Clin Oncol; 2015 Dec; 12(12):693-704. PubMed ID: 26196250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
    Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
    Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial experience with genomic profiling of heavily pretreated breast cancers.
    Staren ED; Braun D; Tan B; Gupta D; Kim S; Kramer K; Markman M
    Ann Surg Oncol; 2014 Oct; 21(10):3216-22. PubMed ID: 25047475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
    Kaur P; Porras TB; Ring A; Carpten JD; Lang JE
    Sci Rep; 2019 Feb; 9(1):1482. PubMed ID: 30728399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
    André F; Bachelot T; Commo F; Campone M; Arnedos M; Dieras V; Lacroix-Triki M; Lacroix L; Cohen P; Gentien D; Adélaide J; Dalenc F; Goncalves A; Levy C; Ferrero JM; Bonneterre J; Lefeuvre C; Jimenez M; Filleron T; Bonnefoi H
    Lancet Oncol; 2014 Mar; 15(3):267-74. PubMed ID: 24508104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.
    Arnedos M; Scott V; Job B; De La Cruz J; Commo F; Mathieu MC; Wolp-Diniz R; Richon C; Campone M; Bachelot T; Dalenc F; Dessen P; Lacroix L; Lazar V; Soria JC; Delaloge S; Andre F
    Eur J Cancer; 2012 Oct; 48(15):2293-9. PubMed ID: 22840369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
    Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling of breast cancers.
    Curtis C
    Curr Opin Obstet Gynecol; 2015 Feb; 27(1):34-9. PubMed ID: 25502431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.
    Levin MK; Wang K; Yelensky R; Cao Y; Ramos C; Hoke N; Pippen J; Blum JL; Brooks B; Palmer G; Palma N; Balasubramanian S; Ross JS; O'Shaughnessy J
    Cancer Med; 2015 Aug; 4(8):1289-93. PubMed ID: 25871911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
    Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
    Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".
    Savas P; Teo ZL; Lefevre C; Flensburg C; Caramia F; Alsop K; Mansour M; Francis PA; Thorne HA; Silva MJ; Kanu N; Dietzen M; Rowan A; Kschischo M; Fox S; Bowtell DD; Dawson SJ; Speed TP; Swanton C; Loi S
    PLoS Med; 2016 Dec; 13(12):e1002204. PubMed ID: 28027312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative genomic analysis reveals bilateral breast cancers are genetically independent.
    Song F; Li X; Song F; Zhao Y; Li H; Zheng H; Gao Z; Wang J; Zhang W; Chen K
    Oncotarget; 2015 Oct; 6(31):31820-9. PubMed ID: 26378809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.